NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Clinical Trial to Compare Forms of MK-1167 in Healthy People (MK-1167-011)

CompletedPhase 1

Sponsor: Merck Sharp & Dohme LLC

Conditions: Healthy

Interventions: MK-1167

Countries: United States

Researchers are looking for new ways to treat Alzheimer's disease (AD). AD is a brain disease that causes a gradual decline in memory, thinking, and ability to carry out daily tasks. MK-1167 is a study medicine designed to treat symptoms of AD. Before giving a study medicine to people with a health condition, researchers first do studies in healthy people to find a safe dose of the study medicine. The goals of the trial are to learn: * What happens to different forms of MK-1167 in a healthy person's body over time * About the safety of MK-1167 and if people tolerate it

Eligibility overview

Sex: ALL

Age: 18 Years to 60 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Is in good health
* Has a body mass index (BMI) ≥18 and ≤ 32 kg/m\^2, inclusive

Exclusion Criteria:

* Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or diseases
* Is a smoker and/or has used nicotine or nicotine-containing products within the past 3 months.

Locations (1)

South Miami, Florida, United States